Takeda To Purchase IDM Pharma To Boost Oncology Business
This article was originally published in PharmAsia News
Executive SummaryTakeda Pharmaceutical May 18 announced a buyout plan to acquire U.S. biopharmaceutical company IDM Pharma. Takeda plans to pay $75 million to obtain all outstanding shares of the Nasdaq-listed company. IDM has obtained approval in the EU for Mepact (mifamurtide), the first treatment approved for osteosarcoma. Through the buyout, Takeda plans to market the drug through marketing branches in Europe and expand its oncology business in the European market. (Click here for more - Japanese language
You may also be interested in...
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.
While contract manufacturer ABH Nature' complied with consent decree, Sen. Chuck Schumer says FDA is late in enforcing against noncompliant firms across the supplement sector. Other recent consumer health recalls include more OTC ranitidine tablets due to the potential carcinogen NDMA found in the heartburn ingredient and four versions of Sure 48HR Anti-Perspirant & Deodorant with labeling errors.
Bioresearchers at the Centers for Disease Control and Prevention are hoping that diagnostic platforms previously used to develop tests for outbreaks of other epidemic respiratory diseases, including SARS and MERS, can be built on to develop new diagnostics to detect more cases in the current coronavirus outbreak, US infectious disease authorities say. This comes as more patients are monitored around the US for the disease, and a Chicago woman returning from China tests positive.